Wednesday, May 22, 2013 Last update: 1:43 AM
Company Tech News as it Breaks
Trade Events
Anacor Pharmaceuticals
News articles for Anacor Pharmaceuticals:
Thursday, May 9, 2013
- Anacor Pharmaceuticals Reports First Quarter 2013 Financial ResultsAnacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the first quarter ended March 31, 2013. “It was an eventful first ... read more
Tuesday, May 7, 2013
- Anacor Pharmaceuticals Announces First Quarter 2013 Financial Results Conference Call and WebcastAnacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the first quarter ended March 31, 2013, on Thursday, May 9, 2013 at approximately 4:00 p.m. ET / 1:00 ... read more
Thursday, May 2, 2013
- Anacor Pharmaceuticals Provides Update Regarding Arbitration With Valeant PharmaceuticalsAnacor Pharmaceuticals (NASDAQ:ANAC) today announced that Valeant Pharmaceuticals International, Inc., or Valeant, has agreed that the launch of efinaconazole, its topical product candidate for the treatment ... read more
Wednesday, May 1, 2013
- Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Over-Allotment OptionAnacor Pharmaceuticals (NASDAQ:ANAC) announced today the completion of its underwritten public offering of 3,129,890 shares of common stock. In addition, Anacor announced that the underwriters of this offering ... read more
Friday, April 26, 2013
- Anacor Pharmaceuticals Prices $20 Million Public Offering of Common StockAnacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has priced an underwritten public offering of 3,129,890 shares of its common stock at a price to the public of $6.39 ... read more
Monday, April 8, 2013
- Anacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease ResearchAnacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to ... read more
Thursday, March 21, 2013
- Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic DermatitisAnacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study ... read more
Wednesday, March 20, 2013
- Anacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of AdolescentsAnacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the Phase 2 dose-ranging study of AN2728 in the treatment of adolescents with atopic dermatitis tomorrow, March 21, 2013 at ... read more
Thursday, March 14, 2013
- Anacor Pharmaceuticals Reports 2012 Fourth Quarter and Year-End Financial ResultsAnacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2012. “With the positive ... read more
Thursday, March 7, 2013
- Anacor Pharmaceuticals Announces 2012 Fourth Quarter and Year End Financial Results Conference Call and WebcastAnacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2012, on Thursday, March 14, 2013 at approximately 4:00 p.m. ET ... read more
Thursday, February 28, 2013
- Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for OnychomycosisAnacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for ... read more
Monday, February 25, 2013
- Anacor Pharmaceuticals to Present at the Cowen 33rd Annual Healthcare ConferenceAnacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the Cowen 33rd Annual Healthcare Conference on Monday, ... read more
Tuesday, January 29, 2013
- Anacor Pharmaceuticals Announces Positive Results From the First of Two Phase 3 Trials of Tavaborole for OnychomycosisAnacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the ... read more
Monday, January 28, 2013
- Anacor Pharmaceuticals to Hold Conference Call Tomorrow, January 29, 2013 at 8AM ET to Discuss Preliminary Results from the First Phase 3 Study of Tavaborole for the Treatment of OnychomycosisAnacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the first of two Phase 3 studies of tavaborole for onychomycosis tomorrow, January 29, 2013 at approximately 7:00 a.m. ET. ... read more
Thursday, January 17, 2013
- Anacor Pharmaceuticals Co-Founder Lucy Shapiro Awarded National Medal of ScienceAnacor Pharmaceuticals (NASDAQ:ANAC) today announced that its co-founder and board member, Dr. Lucy Shapiro was named as a recipient of the National Medal of Science, one of the ... read more
Monday, December 10, 2012
- Anacor Pharmaceuticals Announces Positive Results From Phase 2 Trial of AN2728 in Adolescents With Atopic DermatitisAnacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 safety, pharmacokinetics (PK), and efficacy trial of its boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728, in ... read more
Tuesday, December 4, 2012
- Anacor Announces Second Development Candidate in Animal Health Under Research Collaboration With Eli Lilly and CompanyAnacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has achieved its second development candidate in its animal health collaboration with Eli Lilly and Company (Lilly). Anacor’s research ... read more